A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab (bev) as a first-line therapy for patients with metastatic colorectal cancer

被引：0
|
作者：
Sato, Yasushi
Ohnuma, Hiroyuki
Hirakawa, Masahiro
Takahashi, Minoru
Osuga, Takahiro
Takada, Kohichi
Hayashi, Tsuyoshi
Sato, Tsutomu
Miyanishi, Koji
Takimoto, Rishu
Kobune, Masayoshi
Okita, Kenji
Furuhata, Tomohisa
Hirata, Koichi
Kato, Junji
机构：
[1] Sapporo Med Univ, Sch Med, Dept Med Oncol & Hematol, Sapporo, Hokkaido, Japan
[2] Sapporo Kyoritsu Gorinbashi Hosp, Div Gastroenterol, Sapporo, Hokkaido, Japan
[3] Sapporo Med Univ, Sch Med, Dept Surg Surg Oncol & Sci, Sapporo, Hokkaido, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 03期
关键词：
D O I：
10.1200/jco.2014.32.3_suppl.612
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
612
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Comment on ‘Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer’
    M J Molina-Garrido
    C Guillén-Ponce
    British Journal of Cancer, 2011, 104 : 224 - 225
  • [42] Reply: Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
    Feliu, J.
    Barriuso, J.
    BRITISH JOURNAL OF CANCER, 2011, 104 (01) : 226 - 226
  • [43] Bevacizumab in Combination with Capecitabine plus Irinotecan as First-Line Therapy in Metastatic Colorectal Cancer: A Pooled Analysis of 2 Phase II
    Garcia Alfonso, Pilar
    Munoz Martin, Andres
    Alvarez Suarez, Sonsoles
    Blanco Codeidido, Monserrat
    Mondejar Solis, Rebeca
    Tapia Rico, Gonzalo
    Lopez Martin, Pilar
    Martin, Miguel
    ONKOLOGIE, 2013, 36 (06): : 363 - 367
  • [44] A phase I/II study of capecitabine (X), irinotecan (I) and oxaliplatin (O) as first-line therapy in patients (PTS) with advanced or metastatic colorectal cancer (MCRC)
    Maroun, Jean A.
    Jonker, Derek
    Goel, Rakesh
    Cripps, Christine
    Lister, Diane
    Chiritescu, Gabriela
    ANNALS OF ONCOLOGY, 2006, 17 : 119 - 119
  • [45] Oxaliplatin and Capecitabine (CAPOX) in Non Selected Patients With Metastatic Colorectal Cancer (MCRC) After First-line Irinotecan Based Regimen
    Fonseca, P. J.
    Solis, P.
    Vieitez, J. M.
    Izquierdo, M.
    Pardo, P.
    Gutierrez, E.
    Perez, Q.
    Alvarez, C.
    Frunza, M.
    Uriol, E.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S422 - S423
  • [46] Phase I/II study of capecitabine(C)/oxaliplatin(O)/ irinotecan(I) combined with bevacizumab(B) in the first-line treatment of metastatic colorectal cancer (mCRC)
    Ou, K.
    Liu, X.
    Ma, X.
    Gao, L.
    Wang, Q.
    Yang, L.
    ANNALS OF ONCOLOGY, 2023, 34 : S1514 - S1514
  • [47] A phase II study of first-line biweekly capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer
    Puthillath, Ajithkumar
    Mashtare, Terry, Jr.
    Wilding, Gregory
    Khushalani, Nikhil
    Steinbrenner, Lynn
    Ross, Mary Ellen
    Romano, Karen
    Wisniewski, Michelle
    Fakih, Marwan G.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2009, 71 (03) : 242 - 248
  • [48] A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer
    Cabebe, Elwyn C.
    Fisher, George A.
    Sikic, Branimir I.
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (03) : 1082 - 1087
  • [49] Sequential first-line treatment for metastatic colorectal cancer with capecitabine, irinotecan, and bevacizumab: Capecitabine plus bevacizumab (Cape-Bev) versus capecitabine, irinotecan plus bevacizumab (CAPIRI-Bev): The AIO KRK 0110/ML22011 randomized, phase III trial
    Giessen, Clemens Albrecht
    Modest, Dominik Paul
    Stintzing, Sebastian
    von Weikersthal, Ludwig Fischer
    Vehling-Kaiser, Ursula
    Spaeth-Schwalbe, Ernst
    Freiberg-Richter, Jens
    Mayerle, Julia
    Bangerter, Markus
    Denzlinger, Claudio
    Sieber, Markus
    Teschendorf, Christian
    Peuser, Bettina
    Heinemann, Volker
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [50] A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer
    Elwyn C. Cabebe
    George A. Fisher
    Branimir I. Sikic
    Investigational New Drugs, 2012, 30 : 1082 - 1087
12345